DGAP-News
MOLOGEN AG presented subgroup analysis from IMPACT study and design of pivotal IMPALA trial at Gastrointestinal Cancers Symposium 2015
DGAP-News: MOLOGEN AG / Key word(s): Study/Study results
MOLOGEN AG presented subgroup analysis from IMPACT study and design of
pivotal IMPALA trial at Gastrointestinal Cancers Symposium 2015
19.01.2015 / 08:00
---------------------------------------------------------------------
MOLOGEN AG presented subgroup analysis from IMPACT study and design of
pivotal IMPALA trial at Gastrointestinal Cancers Symposium 2015
Berlin, January 19, 2015 - The biotechnology company MOLOGEN AG presented
two posters on the cancer immunotherapy MGN1703 at the Gastrointestinal
Cancers Symposium 2015 in San Francisco, California. The first poster
featured promising data on overall survival of patient subgroups from the
IMPACT study in colorectal cancer. The data suggests that responders to
induction therapy may benefit the most from a switch maintenance treatment
with MGN1703. This is reflected in the pivotal study IMPALA where 'response
to induction therapy' is one of the main inclusion criteria. The second
poster outlined the design of the IMPALA trial, which has been already
started in 2014 and is currently enrolling patients.
"We are pleased that the predictive factors previously shown to indicate a
more promising progression free survival are also applicable for overall
survival. The IMPALA study design is based on these findings. IMPALA will
only include patients with response after induction therapy. These patients
seem to be the best candidates to benefit most from the MGN1703
immunotherapy," said Prof. Dr. Dirk Arnold, MD, Director of the Clinic for
Medical Oncology, Klinik für Tumorbiologie, Freiburg, Germany. He is one of
the study investigators of IMPACT, one of the coordinating study
investigators of IMPALA and also a member of the steering committee of
IMPALA.
Further to the IMPALA trial in colorectal cancer, MGN1703 is being
investigated for first-line maintenance treatment of extensive-stage small
cell lung cancer, a serious cancer disease with high unmet medical need.
IMPULSE, an international randomized controlled trial, is currently
enrolling patients as well.
About IMPACT
IMPACT (Immunomodulatory MGN1703 in Patients with Advanced Colorectal
Carcinoma with Disease Control after Initial First-line Therapy) was a
phase II, randomized, placebo-controlled, double-blind, multicenter
clinical study aiming to determine the efficacy of MGN1703 as switch
maintenance therapy following first-line chemotherapy with or without the
antibody bevacizumab in patients with metastatic colorectal cancer.
MOLOGEN AG presented subgroup analysis from IMPACT study and design of
pivotal IMPALA trial at Gastrointestinal Cancers Symposium 2015
Berlin, January 19, 2015 - The biotechnology company MOLOGEN AG presented
two posters on the cancer immunotherapy MGN1703 at the Gastrointestinal
Cancers Symposium 2015 in San Francisco, California. The first poster
featured promising data on overall survival of patient subgroups from the
IMPACT study in colorectal cancer. The data suggests that responders to
induction therapy may benefit the most from a switch maintenance treatment
with MGN1703. This is reflected in the pivotal study IMPALA where 'response
to induction therapy' is one of the main inclusion criteria. The second
poster outlined the design of the IMPALA trial, which has been already
started in 2014 and is currently enrolling patients.
"We are pleased that the predictive factors previously shown to indicate a
more promising progression free survival are also applicable for overall
survival. The IMPALA study design is based on these findings. IMPALA will
only include patients with response after induction therapy. These patients
seem to be the best candidates to benefit most from the MGN1703
immunotherapy," said Prof. Dr. Dirk Arnold, MD, Director of the Clinic for
Medical Oncology, Klinik für Tumorbiologie, Freiburg, Germany. He is one of
the study investigators of IMPACT, one of the coordinating study
investigators of IMPALA and also a member of the steering committee of
IMPALA.
Further to the IMPALA trial in colorectal cancer, MGN1703 is being
investigated for first-line maintenance treatment of extensive-stage small
cell lung cancer, a serious cancer disease with high unmet medical need.
IMPULSE, an international randomized controlled trial, is currently
enrolling patients as well.
About IMPACT
IMPACT (Immunomodulatory MGN1703 in Patients with Advanced Colorectal
Carcinoma with Disease Control after Initial First-line Therapy) was a
phase II, randomized, placebo-controlled, double-blind, multicenter
clinical study aiming to determine the efficacy of MGN1703 as switch
maintenance therapy following first-line chemotherapy with or without the
antibody bevacizumab in patients with metastatic colorectal cancer.
Aktuelle Themen
Weitere Artikel des Autors
1 im Artikel enthaltener WertIm Artikel enthaltene Werte